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Only a subset of subjects with excessive alcohol consumption develops alcoholic liver disease (ALD). One of the major
risk factors for ALD is the genetic variant of the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene.
Coffee is one of the most commonly consumed beverages, and coffee consumption has been associated with lower levels of
serum alanine aminotransferase. The aim of this study was to investigate the role of coffee drinking and PNPLA3
rs738409 and their association with alcoholic hepatitis (AH) in a well-characterized cohort of subjects from the Transla-
tional Research and Evolving Alcoholic Hepatitis Treatment consortium. AH subjects and heavy drinking controls without
a history of liver disease who were enrolled between May 2013 and May 2016 were included (n 5 339), and the details of
alcohol and coffee consumption were assessed. The PNPLA3 variant was determined among participants of European
ancestry (n 5 183). Relationships between baseline data and AH status were determined, and multivariable logistic regres-
sion modeling was performed. During the study period, 189 cases with AH and 150 heavy drinking controls were prospec-
tively enrolled. The prevalence of regular coffee consumption was signiﬁcantly lower in patients with AH compared to
controls (20% versus 43%; P < 0.0001). The overall minor allele frequency of the PNPLA3 variant was higher in AH
cases. Multivariable logistic regression revealed that coffee consumption and PNPLA3 were signiﬁcantly associated with
AH status at baseline after adjusting for relevant patient characteristics. Conclusion: We found a higher prevalence of AH
among heavy drinkers with PNPLA3 G/G and G/C genotypes regardless of coffee consumption status and a higher preva-
lence of AH among heavy drinkers who were not regular coffee drinkers. These ﬁndings remained after considering rele-
vant baseline patient characteristics. Further studies are needed to conﬁrm our observation. (Hepatology Communications
2018;2:29-34)
Introduction
Alcoholic liver disease (ALD) comprises a spec-trum of disorders in individuals with acuteand chronic alcohol consumption, ranging
from alcoholic steatosis to alcoholic hepatitis (AH)
and cirrhosis.(1) AH is the most ﬂorid manifestation of
ALD and is associated with a high mortality.(1) ALD
only develops in a subset of subjects with excessive
alcohol use, suggesting that other factors in addition to
alcohol are involved in disease pathogenesis.(2) A
recent meta-analysis showed the patatin-like phospho-
lipase domain-containing protein 3 (PNPLA3) variant
(rs738409, C>G) as the main genetic determinant
of alcoholic cirrhosis.(3) In our Translational
Research and Evolving Alcoholic Hepatitis Treat-
ment (TREAT) consortium study (TREAT001;
NCT#02172898),(4) we found a higher overall allelic
Abbreviations: AH, alcoholic hepatitis; ALD, alcoholic liver disease; AST, aspartate aminotransferase; CI, conﬁdence interval; OR, odds ratio;
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frequency of PNPLA3 rs738409 among AH cases
when compared to heavy drinkers without liver disease
(0.34 versus 0.22; P 5 0.007),(4) with PNPLA3 G/C
and G/G genotypes conferring an increased risk for
AH among heavy drinkers.(5)
This genetic variant, however, does not explain all
the risk for AH, suggesting that other genetic or envi-
ronmental factors play a role. Coffee is one of the most
commonly consumed beverages, and coffee drinking
was inversely associated with nonalcoholic and alco-
holic liver cirrhosis.(5-7) Coffee improves serum transa-
minases and is inversely associated with the severity of
steatohepatitis in patients with nonalcoholic fatty liver
disease.(8) The aim of the present study was to investi-
gate the role of coffee drinking and its association with
PNPLA3 rs738409 as risk factors for AH.
Methods
STUDY COHORT
The analyses were performed on subjects who were
recruited as part of the TREAT001 study. Detailed
data were collected on demographics, alcohol use, reg-
ular coffee consumption (deﬁned as subjects who drank
4 times per week for 5 years), and laboratory values,
as described.(4) We used the following criteria for AH
diagnosis: (1) average daily ethanol consumption of
>40 and >60 grams/day for women and men, respec-
tively; (2) consuming alcohol for at least 6 months and
within the 6 weeks before enrollment; and (3) total bil-
irubin >2 mg/dL and aspartate aminotransferase
(AST) >50 U/L at admission.(4) Controls were
recruited from the Fairbanks Drug and Alcohol Treat-
ment Center (Indianapolis, IN). They were at least 21
years old without underlying medical illnesses, such as
chronic obstructive pulmonary disease, congestive
heart failure, diabetes, cancer, or chronic renal failure.
These subjects had normal results for AST, alanine
aminotransferase, total bilirubin, albumin, platelet
count, and international normalized ratio and had no
past history of jaundice or signs of portal
hypertension.(4)
GENOTYPING FOR PNPLA3
Determination of PNPLA3 rs738409 (C>G) poly-
morphism was performed using the Illumina MEGA
BeadChip (Illumina Inc., San Diego, CA) at the
Mammalian Genotyping Core, University of North
Carolina at Chapel Hill.
STATISTICAL ANALYSIS
Basic descriptive statistics, including mean, SD, and
frequencies (percentages) were used to characterize the
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data set. The chi-square and Student t tests were used
for comparison between groups for categorical and con-
tinuous variables, respectively. We examined the relation
of AH with variables of interest by ﬁrst comparing the
prevalence of AH among the levels of these variables. To
further study the strength and form of association
between coffee consumption and PNPLA3 gene status,
we employed multivariable logistic regression modeling
that controlled for the potential effects of other variables
related to AH. The modeling procedure was conducted
as follows: First, the variables PNPLA3, coffee con-
sumption, body mass index, age, and sex were tested in
univariate models (race was not included because all
patients with PNPLA3 information were Caucasian)
with AH status at baseline as the outcome. Clinical and
laboratory results were not included as potential adjust-
ments because it is well known that these variables are
associated with AH status and this was not our primary
focus. Variables for which the univariate P satisﬁed P <
0.20 were considered for inclusion in the ﬁnal multivari-
able model. Next, all possible models composed of com-
binations of main effects from the screened variables
were ﬁt, and the model with the minimumAkaike infor-
mation criterion was selected as optimal.(9) After selec-
tion of the optimal model, an interaction term between
PNPLA3 and coffee consumption was added to assess
evidence for its inclusion in the ﬁnal model. The
resulting model was then used to calculate the odds
ratios (ORs) and 95% conﬁdence intervals (CIs). A P
value of <0.05 was considered statistically signiﬁcant in
the ﬁnal multivariable model. All analyses were per-
formed with SAS software version 9.3 (Cary, NC).
Results
CLINICAL CHARACTERISTICS
During the study period fromMay 2013 to May 2016,
189 cases with AH and 150 controls were prospectively
enrolled. The detailed demographic and clinical charac-
teristics of the study cohort are summarized in Table 1.
Among regular coffee drinkers, the average duration of
regular coffee consumption for controls and cases with
AH was 26.76 12.6 and 26.36 13.8 years, respectively.
Controls drank 3.4 6 2.1 (mean 6 SD) cups, while
cases with AH consumed2.66 3.0 cups daily.
MULTIVARIATE LOGISTIC
REGRESSION MODELING
All patient characteristic variables, namely age, body
mass index, and sex, did not pass the univariate screen
for inclusion into the ﬁnal multivariable model. Only
TABLE 1. BASELINE DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE STUDY COHORT
Variables
Controls
(n 5 150)
AH Cases
(n 5 189) P Value
Age (years) 44.2 6 12.3 46.7 6 11.0 NS
Men, n (%) 95 (63.3%) 113 (59.8%) NS
Race, Caucasian, n (%) 126 (84.0%) 165 (87.3%) NS
BMI (kg/m2) 28.6 6 7.1 29.3 6 8.3 NS
Regular coffee consumption, n (%) 65 (43.3%) 38 (20.4%) <0.0001
PNPLA3 CC GC GG CC GC GG 0.03
57
(61.3%)
32
(34.4%)
4
(4.3%)
39
(43.3%)
41
(45.6%)
10
(11.1%)
WBC (3103 cells/mm3) 7.2 6 2.6 11.4 6 7.9 <0.0001
Hemoglobin (g/dL) 13.0 6 2.1 10.1 6 2.0 <0.0001
Platelet counts (3103 cells/mm3) 244.2 6 71.8 144.2 6 85.7 <0.0001
Total bilirubin (mg/dL) 0.5 6 0.3 13.9 6 11.5 <0.0001
INR 1.0 6 0.2 1.8 6 0.5 <0.0001
AST (U/L) 27.7 6 9.2 140.1 6 88.2 <0.0001
ALT (U/L) 25.8 6 10.4 62.9 6 65.8 <0.0001
Alkaline phosphatase (U/L) 76.1 6 31.3 193.6 6 138.1 <0.0001
Albumin (g/dL) 3.9 6 0.6 2.8 6 0.7 <0.0001
Total protein (g/dL) 6.5 6 0.8 6.1 6 0.9 <0.0001
Creatinine (mg/dL) 0.9 6 0.3 1.0 6 0.9 NS
MELD Scores 7.1 6 2.3 22.1 6 7.0 <0.0001
Severity of liver diseases (MELD >20), n (%) 0 110 (58%) NA
Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; INR, international normalized ratio; MELD, Model for End-
Stage Liver Disease; WBC, white blood count.
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PNPLA3 and coffee consumption exhibited univariate
P values less than 0.20 (P 5 0.0156 and P 5 0.0036,
respectively; Table 2). The multivariable logistic
regression model that included only the main effects
for coffee consumption and PNPLA3 status was
selected as optimal and provided a better ﬁt than the
multivariable logistic regression model that included
the main effects and an interaction (Akaike informa-
tion criterion, 245.78 versus 247.75, respectively). The
results implied by the ﬁnal multivariable model are
summarized in the following subsections.
PNPLA3 POLYMORPHISM IN AH
AND CONTROLS
The distribution of the PNPLA3 CC, CG, and GG
genotypes(10) and its allelic frequencies were deter-
mined in a subset of 90 cases with AH and 93 controls
of European ancestry.(4) The overall minor allele fre-
quency of PNPLA3 rs 738409 was 0.34 and 0.22 for
AH cases and controls, respectively. We found evi-
dence that the distribution of PNPLA3 varied by AH
case status. Particularly, it seems that a higher percent-
age of AH cases have at least one G variant (P 5
0.0301; Table 1). In the multivariable analyses, the
presence of the GG/GC allele was associated with
increased prevalence of AH (OR, 2.00; 95% CI, 1.09-
3.65; Table 2) after adjusting for coffee consumption.(4)
COFFEE CONSUMPTION AND AH
We found that the prevalence of regular coffee con-
sumption was signiﬁcantly lower in patients with AH
when compared to controls (20% versus 43%; P <
0.0001; Table 1). The association persisted in the mul-
tivariable logistic regression analysis after adjusting for
PNPLA3 polymorphism (OR, 0.41; 95% CI, 0.21-
0.77; Table 2).
INTERACTION BETWEEN PNPLA3
POLYMORPHISM AND COFFEE
CONSUMPTION AND THE RISK
FOR AH
We investigated the relationship between PNPLA3
polymorphism and coffee consumption and the preva-
lence of AH among the pooled cohort of 183 heavy
drinkers with and without AH. Among heavy drinkers
who carried the PNPLA3 CC genotype and were regu-
lar coffee drinkers, the prevalence of AH was 27%.
The prevalence estimate increased to 86% for nonregu-
lar coffee drinkers with the PNPLA3 GG genotype;
however, multivariable logistic regression modeling
showed that there was insufﬁcient evidence for inclu-
sion of an interaction effect between PNPLA3 and
coffee consumption, after adjusting for relevant base-
line characteristics.
Discussion
ALD, a major complication of excessive alcohol use,
is one of the leading causes of chronic liver disease
with substantial morbidity and mortality.(11) Contin-
ued drinking can lead to alcoholic cirrhosis in up to
15%-20% of excessive drinkers in their lifetime,(12)
suggesting that other factors in addition to excessive
alcohol drinking are involved in progression. We found
an important gene (PNPLA3) and environmental (cof-
fee drinking) effect and an association with AH among
those who consume alcohol heavily. Although previous
studies have shown independent relationships between
PNPLA3 variants(3) and coffee drinking and various
TABLE 2. UNIVARIATE MODEL RESULTS AND MULTIVARIABLE MODEL ESTIMATES (PNPLA3 VARIANT
AND COFFEE CONSUMPTION AND THEIR ASSOCIATION WITH AH)
Variable Estimate
Standard
Error P Value Odds Ratio
95% CI
Lower Upper
Univariate Models
Age 0.02 0.01 0.21 1.01 0.99 1.04
Body mass index 0.007 0.02 0.70 1.00 0.97 1.05
Sex (female vs male) –0.08 0.30 0.78 0.92 0.51 1.67
PNPLA3 genotype (GG/GC vs CC) 0.73 0.30 0.01 2.07 1.15 3.74
Coffee consumption –0.93 0.32 0.004 0.39 0.21 0.74
Multivariable Model
PNPLA3 variant (GC/GG vs CC) 0.69 0.31 0.02 2.00 1.09 3.65
Coffee consumption
(Yes vs No)
–0.90 0.33 0.005 0.41 0.21 0.77
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liver diseases,(8,13) to our knowledge this is the ﬁrst
report to investigate them together as risk factors for
AH.
The PNPLA3 gene is located on the long arm of
chromosome 22.(14) PNPLA3 rs738409 (C>G) has
been shown to be associated with alcoholic cirrho-
sis,(15-17) and we have found that those patients with
the GG/GC allele are associated with AH. Our obser-
vation that coffee drinking may exert a protective effect
against AH is interesting and deserves further discus-
sion. Several studies have found an inverse relationship
between coffee consumption and levels of gamma glu-
taryltransferase.(18,19) In patients with chronic hepatitis
C infection, higher coffee consumption was associated
with less steatosis on liver biopsy, lower serum AST/
alanine aminotransferase ratio, and lower alpha-
fetoprotein and insulin.(20) Increasing coffee intake was
associated with a decrease in adverse outcomes, such as
ascites, liver disease-related death, and complications
of portal hypertensions, or a 2-point increase in the
Ishak ﬁbrosis score during follow-up biopsies in
patients with hepatitis C infection.(20) Mechanistically,
it was shown that caffeine, the main component found
in coffee, has anti-inﬂammatory properties.(13,21)
Treatment with caffeine signiﬁcantly attenuated the
increase in serum aminotransferases and ameliorated
hepatocyte damage and hepatic steatosis through inhi-
bition of lipogenic genes in ethanol-fed mice.(21) Fur-
ther, caffeine reduces intrahepatic lipid content and
stimulates b-oxidation in hepatocytes by an autoph-
agy–lysosomal pathway.(22) In mice fed a high-fat diet,
caffeine markedly reduced steatosis by inducing
autophagy and lipid uptake in lysosomes.(22) Caffeine
can also inhibit the production of tumor necrosis factor
a and reactive oxygen species by Kupffer cells.(21)
Lastly, caffeine’s protective mechanism may be medi-
ated through its antagonistic effect on adenosine recep-
tors and thus inhibition of collagen synthesis by
hepatic stellate cells.(23) While caffeine might be the
mechanistically important component of coffee, some
studies have suggested that the protective effect of cof-
fee against hepatic injury may be secondary to
noncaffeine-mediated mechanisms,(13,24) as demon-
strated by the protective effects of decaffeinated coffee.
However, the evidence is weaker overall for decaffein-
ated than for regular coffee.(13)
Our results suggest that coffee drinking favorably
modiﬁes the adverse effects of PNPLA3 minor alleles
among heavy drinkers, but the mechanistic basis for
this phenomenon is unclear. PNPLA3 plays a role in
the hydrolysis of glycerolipids, and its variant leads to a
loss of this function.(14) The PNPLA3 variant also is
associated with the presence of large hepatic lipid
droplets, and the accumulation of inactive PNPLA3
on lipid droplets may cause hepatic triglyceride accu-
mulation.(25) It is plausible that heavy drinkers with
the PNPLA3 variant who are not regular coffee
drinkers may have increased lipogenesis; however, they
may not be able to effectively export the increase in the
amount of lipid leading to subsequent liver injury. This
hypothesis warrants further mechanistic investigation.
Our study has several strengths and limitations. The
strengths are the prospective study design. We also
included a cohort of heavy drinker controls without a
history or laboratory evidence of liver disease. We
acknowledge several limitations of our study. First, the
self-reported questionnaire was determined at baseline
at the time of enrollment, and we did not capture
long-term or lifetime coffee consumption. Addition-
ally, we do not have information on decaffeinated cof-
fee consumption in our study cohort. Second, the
diagnosis of AH was based on clinical criteria as
reported by the TREAT consortium(4) instead of using
liver biopsy. Given the lack of histopathologic ﬁnding,
we cannot rule out the possibilities that the PNPLA3
GG variant may be associated with underlying alco-
holic cirrhosis rather than AH. Third, our sample size
is relatively small. Despite this limitation, we found a
higher prevalence of those with the GG variant in AH
subjects.
In conclusion, we found a higher prevalence of AH
among heavy drinkers with the PNPLA3 GG and GC
genotypes, regardless of coffee consumption status,
and a higher prevalence of AH among heavy drinkers
who are not regular coffee drinkers, regardless of
PNPLA3 status. We recommend that our observations
be conﬁrmed by other investigators and that in vitro
and in vivo experiments be undertaken to further
explore the interaction between PNPLA3 variants and
coffee drinking and the risk for ALD.
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